N. Conev

发表

Impact of travel burden on clinical outcomes in lung cancer

D. Stoyanov, N. Conev, I. Donev, 2022, Supportive Care in Cancer.

The role of carboxylesterase enzymes in capecitabine therapy

N. Conev, P. Marinov, S. Stoeva, 2020 .

One-minute time interval estimation as a novel potent indicator of emotional concerns in cancer patients prior to starting chemotherapy

D. Stoyanov, N. Conev, I. Donev, 2019, Current Psychology.

Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies

S. Sirakov, G. Valchev, N. Conev, 2018 .

Expression of hepatic HMGB1 levels in fructose-induced fatty liver

G. Stoyanov, N. Conev, I. Donev, 2018, Varna Medical Forum.

Association Between Serum CK-18 Levels and the Degree of Liver Damage in Fructose-Induced Metabolic Syndrome.

G. Stoyanov, S. Nikolova, N. Conev, 2018, Metabolic syndrome and related disorders.

Dynamic change of NT- PROBNP in patients with ST-elevation myocardial infarction treated with primary coronary intervention

Veselin D Valkov, N. Conev, I. Donev, 2016 .

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Young Hak Kim, N. Reinmuth, A. Chiang, 2019, The Lancet.

PL02.11 Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study

N. Reinmuth, N. Shire, Haiyi Jiang, 2019, Journal of Thoracic Oncology.

LBA61 Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study

N. Reinmuth, Yuh-Min Chen, L. Paz-Ares, 2021, Annals of Oncology.

Neurotoxicity of cancer agents

S. Sirakov, D. Stoyanov, N. Conev, 2018 .

Single Nucleotide Polymorphisms in microRNA Genes and Colorectal Cancer Risk and Prognosis

N. Conev, I. Donev, G. Mihaylova, 2022, Biomedicines.

Embolization of bronchial arteries in cases of life-threatening bleeding

S. Sirakov, G. Valchev, N. Conev, 2015 .

One-minute time interval estimation as a novel potent indicator of emotional concerns in cancer patients prior to starting chemotherapy

D. Stoyanov, N. Conev, I. Donev, 2019, Current Psychology.

Serum expression levels of miR-17, miR-21, and miR-92 as potential biomarkers for recurrence after adjuvant chemotherapy in colon cancer patients.

T. Chervenkov, N. Conev, I. Donev, 2015, Bioscience trends.

Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second‐line pembrolizumab in patients with non‐small‐cell lung cancer

M. Petrova, N. Conev, I. Donev, 2020, Clinical and experimental immunology.

Neutrophil to lymphocyte ratio as a potential predictive marker for treatment with pembrolizumab as a second line treatment in patients with non-small cell lung cancer.

M. Petrova, K. Koynov, N. Conev, 2020, Bioscience trends.

Circulating Histones to Detect and Monitor the Progression of Cancer

M. Vinciguerra, D. Stoyanov, N. Conev, 2023, International journal of molecular sciences.

FIRST LINE 5-FU-BASED CHEMOTHERAPY WITH/ WITHOUT BEVACIZUMAB FOR METASTATIC COLORECTAL CANCER: TISSUE BIOMARKER CANDIDATES

N. Conev, I. Donev, A. Konsoulova, 2016 .

FIRST LINE 5!FU!BASED CHEMOTHERAPY WITH/ WITHOUT BEVACIZUMAB FOR METASTATIC COLORECTAL CANCER: ONE CENTER EXPERIENCE RESULTS

T. Chervenkov, N. Conev, I. Donev, 2015 .

Role of the pretreatment 18F-fluorodeoxyglucose positron emission tomography maximal standardized uptake value in predicting outcomes of colon liver metastases and that value's association with Beclin-1 expression.

N. Conev, I. Donev, B. Chaushev, 2017, Bioscience trends.

Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.

N. Reinmuth, Haiyi Jiang, N. Byrne, 2020, The Lancet. Oncology.

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

H. Mann, M. Hochmair, L. Havel, 2022, ESMO open.

Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report

N. Reinmuth, Haiyi Jiang, L. Paz-Ares, 2022, JTO clinical and research reports.

LBA86 Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN

N. Reinmuth, Y. Shrestha, Yuh-Min Chen, 2020 .

Childhood obesity, renal injury and future disease risk

V. Iotova, M. Lateva, G. Yordanova, 2014 .

RIPK3 expression as a potential predictive and prognostic marker in metastatic colon cancer.

K. Kalchev, N. Conev, I. Donev, 2019, Clinical and investigative medicine. Medecine clinique et experimentale.

Levels of miR-17, miR-21, miR-29a and miR-92 as recurrence markers after adjuvant chemotherapy in Nx lymph node status colon cancer patients

N. Conev, I. Donev, I. Tonev, 2016 .

New Circulating Circular RNAs with Diagnostic and Prognostic Potential in Advanced Colorectal Cancer

D. Ivanova, G. Stoyanov, N. Conev, 2021, International journal of molecular sciences.

One-minute time interval estimation as a novel ultrashort tool for distress screening

D. Stoyanov, N. Conev, I. Donev, 2018, Supportive Care in Cancer.

Rare case of ameloblastoma with pulmonary metastases.

N. Conev, I. Donev, I. Valkadinov, 2017, Intractable & rare diseases research.

Association of rs363293 single nucleotide polymorphism in promoter region of miRNA-143/145 with susceptibility to colorectal cancer and with patients’ outcome

D. Ivanova, N. Conev, I. Donev, 2019, Annals of Oncology.

Fast time perception is associated with high levels of anxiety in cancer patients prior to starting chemotherapy.

N. Conev, I. Donev, M. Ivanova, 2020, Bioscience trends.

P48.03 First-Line Durvalumab plus Platinum-Etoposide in ES-SCLC: Exploratory Analyses Based on Extent of Disease in CASPIAN

N. Reinmuth, Haiyi Jiang, N. Byrne, 2021 .

2-year single center clinical experience in patients with colon cancer stage II and III receiving adjuvant chemotherapy

N. Conev, I. Donev, D. Kalev, 2015 .

Serum levels of RIPK3 and troponin I as potential biomarkers for predicting impaired left ventricular function in patients with myocardial infarction with ST segment elevation and normal troponin I levels prior percutaneous coronary intervention.

Veselin D Valkov, N. Conev, I. Donev, 2016, Bioscience trends.

Serum levels of RIPK 3 and troponin I as potential biomarkers for predicting impaired left ventricular function in patients with myocardial infarction with ST segment elevation and normal troponin I levels prior percutaneous coronary intervention

Veselin D Valkov, N. Conev, I. Donev, 2016 .

Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second‐line pembrolizumab in patients with non‐small‐cell lung cancer

M. Petrova, N. Conev, I. Donev, 2020, Clinical and experimental immunology.

Circulating miR-618 Has Prognostic Significance in Patients with Metastatic Colon Cancer

M. Mirchev, N. Conev, I. Donev, 2021, Current oncology.

Prognostic value of translationally controlled tumor protein in colon cancer

D. Stoyanov, N. Conev, I. Donev, 2023, Molecular and clinical oncology.

Primary Adenoid Cystic Carcinoma of the Skin with Multiple Local Recurrences

N. Conev, I. Tonev, Yana Stoeva Pirgova, 2015, Case Reports in Oncology.

First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes.

N. Byrne, L. Paz-Ares, J. Goldman, 2020 .

KRAS Mutation Status in Bulgarian Patients with Advanced and Metastatic Colorectal Cancer

G. Stoyanov, N. Conev, N. Kolev, 2023, International journal of molecular sciences.

Prevalence and prognosis of PIK3CA mutations in Bulgarian patients with metastatic breast cancer receiving endocrine therapy in first‐line setting

N. Conev, I. Donev, M. Radanova, 2023, Cancer reports.